Tarsus Pharmaceuticals

$27.53 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals Inc. is a late clinical-stage biopharmaceutical company. The Company if focused on the development and commercialization of therapeutic candidates to address ophthalmic conditions. Its lead product candidate, TP-03, is a novel therapeutic being developed for the treatment of blepharitis caused by the infestation of Demodex mites (Demodex blepharitis). It is developing TP-03 as an eye drop. It is also focused on developing additional clinical-stage product candidates, including TP-04 and TP-05. TP-04 is being developed for the treatment of rosacea and TP-05 for Lyme prophylaxis and community malaria reduction.

Stock Analysis

last close $28.42
1-mo return 32.5%
3-mo return 11.5%
avg daily vol. 33.53T
52-week high 63.69
52-week low 17.96
market cap. $587M
forward pe -
annual div. -
roe -5.5%
ltg forecast -
dividend yield -
annual rev. $55M
inst own. 63.8%
baraka

Subscribe now for daily local and international financial news

Subscribe